Felmetatug vedotin

N/A

Report date: 2025/03/19 16:56:42

Base Information

Drug NameFelmetatug vedotin
Drug Alias NameSGN-B7H4VSGN-B-7H-4VSGNB-7H4VSGNB-7H-4VPF-08046048
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsV-set domain-containing T-cell activation inhibitor 1 inhibitors
TargetsTubulinV-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsFallopian Tube Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesSeagen Inc
Active IndicationsSolid tumours
Inactive IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksN/A